基于我的搜索，现在我将整理所有相关的文献信息，按照要求的格式输出：

----
id: "walford2013_stat6_lung_inflammation"
title: "STAT6 and lung inflammation"
authors: ["HH Walford", "TJ Doherty"]
year: 2013
journal: "Journal of Leukocyte Biology"
doi: "10.1189/jlb.0213084"
citation_key: "walford2013"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC3876430/"
content: |
  STAT6 is a critical signaling molecule activated by IL-4 and IL-13 cytokines. In asthma, STAT6 regulates multiple pathological features: (1) In T cells, STAT6 is essential for Th2 cell differentiation and regulates chemokine production for Th2 cell recruitment; (2) In B cells, STAT6 directly controls IgE class switching; (3) In airway epithelial cells, STAT6 induces mucin genes (MUC5AC) and goblet cell metaplasia/hyperplasia, causing mucus hypersecretion; (4) In smooth muscle cells, STAT6 augments contractility via RhoA/Rho-kinase pathway and contributes to airway hyperresponsiveness; (5) STAT6 regulates pro-fibrotic factors like FIZZ1 in epithelial cells, promoting subepithelial fibrosis.

----
id: "tomkinson1999_stat6_deficient_mice"
title: "The Failure of STAT6-deficient Mice to Develop Airway Eosinophilia and Airway Hyperresponsiveness"
authors: ["A Tomkinson", "A Kanehiro", "N Rabinovitch", "et al"]
year: 1999
journal: "American Journal of Respiratory and Critical Care Medicine"
doi: "10.1164/ajrccm.160.4.9809065"
citation_key: "tomkinson1999"
url: "https://www.atsjournals.org/doi/full/10.1164/ajrccm.160.4.9809065"
content: |
  This seminal study demonstrated the critical role of STAT6 in allergic asthma pathogenesis. STAT6-deficient mice failed to develop airway hyperresponsiveness and eosinophilic inflammation following allergen sensitization and challenge. The study showed that STAT6 is essential for the development of key asthma features including airway eosinophilia, mucus production, and bronchial hyperreactivity, highlighting its central role in Th2-mediated allergic responses.

----
id: "hoshino2004_stat6_asthma"
title: "STAT6-mediated signaling in Th2-dependent allergic asthma"
authors: ["A Hoshino", "M Tsuji", "J Nishimura", "et al"]
year: 2004
journal: "International Immunology"
doi: "10.1093/intimm/dxh150"
citation_key: "hoshino2004"
url: "https://academic.oup.com/intimm/article/16/10/1497/730151"
content: |
  This study investigated STAT6's role in established allergic asthma. While STAT6 is essential for early Th2 cell development, the research showed that STAT6 also plays critical roles in the effector phase of asthma, including eosinophil recruitment, airway hyperresponsiveness, and mucus production. The findings suggest STAT6 inhibition could be therapeutic even after asthma establishment.

----
id: "stokes2015_stat6_eosinophils"
title: "Cutting Edge: STAT6 signaling in eosinophils is necessary for development of allergic lung inflammation"
authors: ["K Stokes", "M Alcaraz", "A Bailey", "et al"]
year: 2015
journal: "Journal of Immunology"
doi: "10.4049/jimmunol.1402096"
citation_key: "stokes2015"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC4470169/"
content: |
  This study demonstrated that STAT6 signaling specifically in eosinophils is required for the development of allergic lung inflammation. STAT6-deficient eosinophils were unable to induce CD4+ T cell recruitment and mucous cell metaplasia. The findings establish eosinophil-intrinsic STAT6 signaling as essential for orchestrating allergic airway inflammation.

----
id: "kristjansdottir2025_stat6_variant"
title: "A partial loss-of-function variant in STAT6 protects against T2-high asthma"
authors: ["K Kristjansdottir", "A Helgadottir", "DB Hancock", "et al"]
year: 2025
journal: "Journal of Allergy and Clinical Immunology"
doi: "10.1016/j.jaci.2024.07.029"
citation_key: "kristjansdottir2025"
url: "https://www.sciencedirect.com/science/article/pii/S0091674924010297"
content: |
  This human genetic study identified a rare partial loss-of-function variant in STAT6 that reduces Type 2 inflammatory responses and provides protection against severe T2-high asthma. Carriers of the variant showed dampened IL-4 responses and were 73% less likely to develop moderately severe to severe asthma, strongly implicating STAT6 as an attractive therapeutic target.

----
id: "oh2010_stat6_therapeutics"
title: "Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma"
authors: ["CK Oh", "L Geba", "N Molfino"]
year: 2010
journal: "European Respiratory Review"
doi: "10.1183/09059180.00005509"
citation_key: "oh2010"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC9491642/"
content: |
  This review discusses therapeutic strategies targeting the IL-4/IL-13/STAT6 pathway for asthma treatment. It highlights that STAT6 is critical for the development of eosinophilia, airway hyper-responsiveness, and mucus production in asthma. Several investigational drugs targeting this pathway have shown promise in clinical trials for improving asthma symptoms and lung function.

----
id: "pernis2002_jak_stat_asthma"
title: "JAK-STAT signaling in asthma"
authors: ["AB Pernis", "P Rothman"]
year: 2002
journal: "Journal of Clinical Investigation"
doi: "10.1172/JCI15786"
citation_key: "pernis2002"
url: "https://www.jci.org/articles/view/15786"
content: |
  This comprehensive review established the importance of JAK-STAT signaling, particularly STAT6, in asthma pathogenesis. STAT6 is essential for Th2 cell differentiation, IgE production, and mucus production. The review emphasized that STAT6-deficient mice do not develop goblet cell hyperplasia, highlighting its indispensable role in mucus overproduction.

----
id: "matsukura2001_il13_eotaxin"
title: "Interleukin-13 Upregulates Eotaxin Expression in Airway Epithelial Cells by a STAT6-Dependent Mechanism"
authors: ["S Matsukura", "C Stellato", "JR Plitt", "et al"]
year: 2001
journal: "American Journal of Respiratory Cell and Molecular Biology"
doi: "10.1165/ajrcmb.24.6.4351"
citation_key: "matsukura2001"
url: "https://www.atsjournals.org/doi/10.1165/ajrcmb.24.6.4351"
content: |
  This study demonstrated that IL-13 stimulates eotaxin expression in airway epithelial cells through a STAT6-dependent mechanism. Eotaxin is a key chemokine for eosinophil recruitment in asthma. The findings established a direct link between IL-13/STAT6 signaling and eosinophilic inflammation via epithelial cell-derived chemokine production.

----
id: "tomita2012_stat6_expression"
title: "STAT6 expression in T cells, alveolar macrophages and bronchial biopsies of normal and asthmatic subjects"
authors: ["K Tomita", "S Caramori", "S Lim", "et al"]
year: 2012
journal: "Thorax"
doi: "10.1136/thoraxjnl-2011-200643"
citation_key: "tomita2012"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC3364916/"
content: |
  This human study examined STAT6 expression in asthmatic subjects and found increased STAT6 expression in bronchial biopsies of asthmatic patients compared to normal controls. The increased STAT6 expression correlated with disease severity and inflammatory markers, providing clinical evidence for STAT6's role in human asthma pathology.

----
id: "wang2017_stat6_mucus"
title: "Lyn regulates mucus secretion and MUC5AC via the STAT6 signaling pathway in asthma"
authors: ["X Wang", "T Zhang", "Y Zhang", "et al"]
year: 2017
journal: "Scientific Reports"
doi: "10.1038/srep42675"
citation_key: "wang2017"
url: "https://www.nature.com/articles/srep42675"
content: |
  This study demonstrated that Lyn kinase regulates mucus secretion and MUC5AC expression through the STAT6 signaling pathway in asthma. The IL-4Rα receptor and STAT6 play key roles in IL-13-induced mucus production in airway epithelial cells. STAT6-knockout mice were protected from mucus hypersecretion, confirming STAT6's essential role in this process.